Geographic Area
Alzheimer’s Market Set for Eightfold Boom: Lilly, Eisai, and Biogen Lead the Charge
Alzheimer’s disease market, Eli Lilly, Eisai, Biogen, Market growth, Donanemab (Kisunla), Leqembi
Denmark’s AI and Biotech Advancements: No Direct Information on New Manufacturing Learning Center
Denmark, AI research center, biotech acquisitions, vocational education, manufacturing learning center
Daiichi Sankyo Expands Cancer Research and Manufacturing Capacity in Germany
Daiichi Sankyo, antibody-drug conjugates (ADCs), cancer research, manufacturing capacity, Germany, Pfaffenhofen facility, innovation center
Moderna Slashes 2025 Revenue Forecast, Expands Cost-Cutting Measures Amid Vaccine Sales Decline
Moderna, 2025 revenue forecast, cost-cutting measures, vaccine sales decline, COVID-19 vaccine market competition, falling vaccination rates.
Tenpoint Therapeutics Prepares for 2026 Market Launch Following Successful Phase 3 Trial of BRIMOCHOL PF for Presbyopia Treatment
Tenpoint Therapeutics, BRIMOCHOL PF, Presbyopia treatment, Phase 3 trial, Combination eye drop, 2026 market launch
Bausch + Lomb Collaborates with City Therapeutics on Novel RNAi-Based Treatment for Geographic Atrophy
Bausch + Lomb, City Therapeutics, RNA interference (RNAi), Geographic atrophy (GA), Age-related macular degeneration (AMD), Strategic collaboration, Ophthalmologic diseases
FDA Sets Efficacy Threshold for Obesity Therapies Amid Market Expansion
FDA, obesity therapies, weight-loss treatments, efficacy standards, obesity market trends
Bausch + Lomb Enters Strategic Collaboration with City Therapeutics for RNAi-Based Eye Disease Treatment
Bausch + Lomb, City Therapeutics, RNAi, eye disease, geographic atrophy, age-related macular degeneration, strategic collaboration
National Resilience Lays Off 120 Employees at Former Bluebird Bio Gene Therapy Facility in Durham, North Carolina
National Resilience, Layoffs, Gene Therapy, Bluebird Bio, Durham/ North Carolina, Biotech Industry, CDMO (Contract Development and Manufacturing Organization)
WuXi Biologics Divests Irish Vaccine Facility to Merck for $500 Million Amid Strategic Shift
WuXi Biologics, Merck, vaccine manufacturing facility, Dundalk, Ireland, asset sale, strategic shift, regulatory changes, Biosecure Act